Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2017 · 10-K
Revenue$7.53M$7.53M+69.1% vs Q4 2016 Net Income-$8.82M-$8.82MN/M vs Q4 2016 EPS Diluted-$0.17-$0.17N/M vs Q4 2016 Gross Profit$3,834,999+90.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,766,977N/M Free Cash Flowderived-$4,062,268N/M Margins · derivedGross margin50.9%+5.8 pt vs Q4 2016
Operating margin-116.6%−67.8 pt vs Q4 2016
Net margin-117.1%−68.9 pt vs Q4 2016
ended Dec 30, 2017 · filed Mar 15, 2018 · 75 d after period end